AstraZeneca: Yinjufen officially launched in China.

AstraZeneca announced the official launch of its innovative drug, Engzhuofan, in China. In April of this year, based on the positive results of the global Phase III HIMALAYA study and the Chinese cohort, Tremelimumab combined with Infiwan was approved in China for first-line treatment in adult patients with advanced or unresectable hepatocellular carcinoma.